| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -7,536,598 | -6,761,316 | -7,102,455 | -16,188,206 |
| Stock compensation expense | 2,796,240 | 2,147,467 | 1,445,480 | 2,831,783 |
| Depreciation and amortization | 23,472 | 22,544 | 21,292 | 27,429 |
| Amortization of debt discount | NaN | 481,424 | NaN | NaN |
| Loss on share settlement of kineta employee compensation assumed from merger | NaN | NaN | 185,019 | NaN |
| Loss on share issuance to kineta separation payments | NaN | 185,019 | NaN | NaN |
| Change in fair value of kineta merger holdback shares | NaN | NaN | 315,660 | NaN |
| Change in fair value of holdback shares | NaN | -1,590,948 | NaN | NaN |
| Other current assets | 182,970 | -124,446 | -222,659 | -110,418 |
| Other noncurrent assets | -34,897 | -185,574 | -39,804 | 70,380 |
| Accounts payable and accrued expenses | 452,006 | 150,447 | -6,214,003 | 2,302,372 |
| Net cash flows from operating activities | -4,412,953 | -5,556,022 | -11,086,544 | -10,986,584 |
| Cash paid for kineta acquisition, net of assumed cash | NaN | 0 | 0 | 1,259,278 |
| Purchase of property and equipment | 48,846 | 27,850 | 0 | 48,233 |
| Net cash flows from investing activities | -48,846 | -27,850 | 0 | -1,307,511 |
| Repayment of assumed kineta indeptedness | NaN | 0 | 434,000 | NaN |
| Proceeds from bridge note | NaN | 3,000,000 | NaN | NaN |
| Proceeds from warrants exercised | NaN | 0 | 0 | 3,620,657 |
| Payment of bridge note | NaN | 1,401,323 | 98,677 | NaN |
| Payment of offering costs associated with issuance of common stock | NaN | 1,223,944 | NaN | 331,363 |
| Payment of merger transaction costs | NaN | 0 | 0 | 500,000 |
| Cash dividend payment of preferred stock series a | 2,089 | 2,089 | 2,089 | 4,178 |
| Proceeds from issuance of common stock | 7,500,000 | 6,191,140 | 6,197,547 | 5,914,625 |
| Payments made on kineta severance promissory notes | 197,354 | 394,709 | NaN | NaN |
| Principal payments of finance lease | 10,845 | 10,644 | 43,671 | NaN |
| Payment of placement agent fees and offering costs | -529,602 | NaN | 679,337 | NaN |
| Payment of net liabilities assumed in reverse recapitalization | NaN | 0 | 0 | 550,000 |
| Net cash flows from financing activities | 7,139,977 | 6,506,405 | 5,271,136 | 8,149,741 |
| Net change in cash and cash equivalents | 2,678,178 | 922,533 | -5,815,408 | -4,144,354 |
| Cash and cash equivalents at the beginning of the period | 3,619,949 | 2,697,416 | 12,657,178 | NaN |
| Cash and cash equivalents at the end of the period | 6,298,127 | 3,619,949 | 2,697,416 | NaN |
TuHURA Biosciences, Inc. NV (HURA)
TuHURA Biosciences, Inc. NV (HURA)